登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月12日晚间，*ST沪科发布《关于收到中国证券监督管理委员会立案告知书的公告》。公告显 示：上海宽频科技股份有限公司于2025年12月12日收到中国证券监督管理委员会下发的《立案告知书》 （编号：证监立案字0032025030号）。因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中 华人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 此前在2025年11月28日，*ST 沪科曾发布《关于非经营性资金占用事项的进展公告》，*ST 沪科表示截 至本公告披露日，上海宽频科技股份有限公司原控股股东南京斯威特集团有限公司及其关联方违规占用 上市公司资金余额为人民币348，612，206.20元，占最近一期经审计净资产的921.63%，资金占用问题 全部为 2000 年至 2007 年期间，公司原控股股东南京斯威特集 ...

Core Viewpoint - Guangdong Zijing Information Storage Technology Co., Ltd. has been forced to delist due to major violations, with significant legal consequences for its executives [1][11]. Legal Consequences - The company was fined 37 million RMB for fraudulently issuing securities [4][14]. - The actual controller Zheng Mu received a combined prison sentence of 7 years and 6 months for multiple offenses, including fraud and failure to disclose important information [4][14]. - Other executives, including Luo Tiewei and Li Yanxia, received varying prison sentences, with the highest being 7 years for Luo Tiewei [5][15]. Company Background - Zijing Storage was established on April 15, 2010, and primarily engaged in the research, manufacturing, and sales of storage devices [6][18]. - The company was listed on the National Equities Exchange and Quotations (NEEQ) in April 2016 and later on the Sci-Tech Innovation Board in February 2020, raising a total of 1.023 billion RMB [7][19]. Financial Misconduct - From 2017 to 2019, the company engaged in financial fraud, including inflating revenue and profits through false contracts and documents [7][19]. - The inflated profits accounted for 34.83% of total profits in 2017 and 32.25% in 2018, with 42.97% of revenue in the first half of 2019 being fraudulent [8][19]. Performance Decline - After going public, the company's performance deteriorated, with a revenue drop of 6.69% in 2021 and a net loss of 229 million RMB, a decline of 379.85% [8][20]. - The company faced regulatory scrutiny and was investigated for information disclosure violations, leading to its delisting in July 2023 [9][20]. Investor Compensation - The case set a precedent for investor compensation in the Sci-Tech Innovation Board, with intermediary institutions committing 1.275 billion RMB for investor payouts [9][21]. - By June 30, 2023, 97.22% of affected investors had reached settlements, receiving a total of 1.086 billion RMB in compensation [9][21].

公告称，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大影响。 公司将积极配合中国证监会立案调查工作，并按照有关法律法规等规定和要求，及时做好信息披露。 2025年前三季度，*ST沪科共实现营业收入544.03万元，同比下降63.7%；实现归属于上市公司股东的净 利润为106.2万元，同比增长448.84%。 12月12日晚，*ST沪科发布公告称，公司收到中国证券监督管理委员会下发的《立案告知书》。因涉嫌 信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国 证券监督管理委员会决定对公司立案。 值得一提的是，*ST沪科于11月28日晚间对外披露关于非经营性资金占用事项的进展公告。公告显示， 截至公告披露日，公司原控股股东南京斯威特集团有限公司及其关联方违规占用上市公司资金余额约为 3.49亿元，占最近一期经审计净资产的921.63%。公司拟通过公开挂牌转让所持有的南京斯威特集团及 其关联公司因历史遗留问题产生的全部债权及其他或有债权，同时解除公司全部或有负债。上述事项尚 需通过国资委备案、董事会、股东大会审议批准，并以公开挂牌转让方式实施，能否 ...

Core Viewpoint - *ST HuKe is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, which adds to the company's existing delisting risk [2][4]. Group 1: Company Status - As of December 12, *ST HuKe's stock price was 3.81 yuan, with a market capitalization of 1.253 billion yuan, reflecting a decline of 0.26% [4]. - The company has been facing delisting risks since April 30, when its stock was flagged due to negative audited profit totals and revenues below 300 million yuan [6]. - The company reported a significant decline in operating scale, with revenues dropping from 367 million yuan in 2022 to 17 million yuan in 2024 [4][6]. Group 2: Financial Performance - The company is projected to incur continuous losses, with net profits of -22.015 million yuan in 2023 and -5.6828 million yuan in 2024 [4]. - For the first three quarters of 2025, *ST HuKe's revenue was only 5.4403 million yuan, representing a year-on-year decline of 63.70%, with a non-recurring net profit of -237,200 yuan [6]. - The decline in revenue is attributed to decreased income from both chemical and agricultural product trading, as well as increased contract penalties in the agricultural sector [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 投资快报记者 黄敏 广州报道 突发！12月12日晚间，上海宽频科技股份有限公司（*ST沪科，600608）公告称，公司于2025年12月12 日收到中国证券监督管理委员会下发的《立案告知书》。因涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 公告称，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大影响。 公司将积极配合中国证券监督管理委员会立案调查工作，并按照有关法律法规等规定和要求，及时做好 信息披露工作。敬请广大投资者注意投资风险。 据了解，*ST沪科主营业务以农产品、化工产品等产品的商品贸易为主，根据中国证监会《上市公司行 业分类指引》（2012年修订），公司所处行业属于"F51批发业"。2025年上半年公司农产品业务以鲜切 花和酒粮类产品为主，化工产品以钛白粉产品为主。 事实上，*ST沪科基本面并不乐观，此次涉嫌信披违规被立案调查可谓"雪上加霜"。该公司2025年三季 报显示，公司第三季度营收为104万元，同比降56.95%；归属于上市公司的 ...

Core Viewpoint - *ST沪科 has received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws, which the company claims will not significantly impact its operations and management [1][2]. Financial Performance - In the first three quarters of the year, *ST沪科 reported revenue of only 5.44 million, a year-on-year decline of 63.7%, while the net profit attributable to shareholders was 1.06 million, showing a significant increase [2]. - The company's revenue dropped sharply from 367 million in 2022 to 17.23 million in 2024, falling below 100 million [2]. - Continuous losses are expected for the years 2023 and 2024, with a risk of delisting if the total profit, net profit, or net profit after excluding non-recurring gains and losses is negative and revenue is below 300 million in 2025 [2]. Management Changes - Following the resignation of Yun Feng, the company’s board secretary and financial officer, the chairman Wang Tianyang is temporarily taking over the secretary duties, while financial manager Yang Xiuxin is acting as the financial officer [3]. - Yun Feng, who was appointed as a director in March 2024 and took on the roles of board secretary and financial officer in November, resigned due to personal health reasons after just over a year in these positions [3]. - Other significant management changes include the resignation of the chairman Zhang Lu in April and independent director Li Zheng in August, both citing personal reasons [3]. Shareholder Issues - The second-largest shareholder, Kunming Industrial Development Investment Co., Ltd., has had all its shares frozen, and the first-largest shareholder's shares are also under freeze [3]. - As of October, the former controlling shareholder, Nanjing Siweit Group Co., Ltd., and its affiliates had illegally occupied 349 million of the company's funds, accounting for 921.63% of the latest audited net assets [4].

Group 1 - *ST Hu Ke announced on December 12, 2025, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws [1][3] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management [3] - The main business of *ST Hu Ke focuses on the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [3] Group 2 - For the third quarter, *ST Hu Ke reported a revenue of 1.04 million yuan, a year-on-year decrease of 56.95%, with a net profit attributable to shareholders of 1.0271 million yuan [4] - As of December 12, 2025, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [4] Group 3 - On the same day, Renfu Pharmaceutical announced it received a notice of administrative penalty from the CSRC for failing to disclose non-operating fund occupation and significant omissions in its annual reports for 2020 and 2022 [7] - Renfu Pharmaceutical's stock will be subject to risk warnings starting December 16, 2025, with a trading limit of 5% on price fluctuations [7][9] - The company, established in 1993, is a leading pharmaceutical enterprise in Hubei Province, focusing on a full industrial chain from intermediates to drug formulations [9] Group 4 - As of December 12, 2025, Renfu Pharmaceutical's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

*ST沪科（600608）(600608.SH)发布公告，公司于2025年12月12日收到中国证券监督管理委员会下发的 《立案告知书》(编号:证监立案字0032025030号)。因涉嫌信息披露违法违规，根据《中华人民共和国证 券法》《中华人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 ...

*ST沪科公告，公司于2025年12月12日收到中国证券监督管理委员会下发的《立案告知书》。因涉嫌信 息披露违法违规，中国证券监督管理委员会决定对公司立案。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 根据公开市场数据，海德股份（维权）近期两融余额有所波动。值得关注的是，该公司已于早些时候因 涉嫌信披违规被监管立案。2025年11月28日，海南海德资本管理股份有限公司发布《关于公司及相关人 员收到中国证券监督管理委员会<立案告知书>的公告》。公告显示，公司及实际控制人王广西于当日 收到中国证监会下发的《立案告知书》（编号：证监立案字0292025006号和0292025007号）。因涉嫌信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司及实际控制人立案调查。 对此，上海百悦律师事务所牛彬律师表示，海德股份因涉嫌信息披露违法违规被证监会立案调查，根据 相关法律规定，受损投资者有权依法要求赔偿。暂定索赔条件为：在2025年4月28日之前买入海德股份 （000567）股票，并在2025年4月2 ...